All In Biotech

Drug Trial Radar · NCT00338286

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Last checked: Nov 19, 2026Latest source record: Mar 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,098 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,098

Actual

Start

Mar 2, 2006

Primary completion

Jul 7, 2014

Study completion Jan 31, 2017

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guidance in patients with metastatic breast cancer receiving standard chemotherapy.

Conditions

  • Breast Cancer
  • Neoplasm Metastasis

Interventions

  • Standard supportive care (packed RBC transfusion)Other

    Per doctor prescription

  • epoetin alfa + packed RBC transfusionDrug

    40,000 IU SC once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: From the date of randomization to the date of disease progression (PD) or death, whichever occurred first (up to 8.4 years)

Locations

174 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Anaheim, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Rockledge, Florida

  • Site not named

    Hazard, Kentucky

  • Site not named

    Alexandria, Louisiana

  • Site not named

    Marrero, Louisiana

  • Site not named

    Jackson, Mississippi

  • Site not named

    Lake Success, New York

  • Site not named

    Staten Island, New York

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Corpus Christi, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Capital Federal, Argentina

  • Site not named

    Ciudad Autonoma de Buenos Airess, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    La Plata, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Quilmes, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    Santa Fe, Argentina

  • Site not named

    Barretos, Brazil

  • Site not named

    Curitiba, Brazil

  • Site not named

    Goiânia/Go, Brazil

  • Site not named

    Ijuí, Brazil

  • Site not named

    Jaú, Brazil

  • Site not named

    Piracicaba, Brazil

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Ribeirão Preto/Sp, Brazil

  • Site not named

    Santo André, Brazil

  • Site not named

    São José do Rio Preto, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    São Paulol, Brazil

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Stara Zagora, Bulgaria

  • Site not named

    Varna, Bulgaria

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.